CNAT Conatus Pharmaceuticals Inc.

5.17
-0.09  -2%
Previous Close 5.26
Open 5.26
Price To book 7.07
Market Cap 135.29M
Shares 26,169,000
Volume 329,823
Short Ratio 3.53
Av. Daily Volume 932,639

SEC filingsSee all SEC filings

  1. 424B5 - Prospectus [Rule 424(b)(5)] 17835501
  2. 8-K - Current report 17835336
  3. 424B5 - Prospectus [Rule 424(b)(5)] 17831648
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 17815606
  5. 8-K - Current report 17813899

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 enrollment commenced - March 15, 2017.
JZP-258
Cataplexy and Excessive Daytime Sleepiness in Narcolepsy
Phase 2b data due 2019.
Emricasan
NASH cirrhosis - ENCORE-LF trial
Phase 2b initiated November 2016. Data due 2018.
Emricasan
NASH cirrhosis - ENCORE-PH trial
Phase 2 topline data released Jan 2015
Emricasan
Acute-on-Chronic Liver Failure (ACLF)
Phase 2 data released September 2015.
Emricasan
Portal Hypertension
Phase 2b initiated May 2014. Topline data due 1H 2018.
Emricasan
Liver fibrosis post-orthotopic liver transplant due to Hepatitis C virus infection (HCV-POLT)
Phase 2 trial initiated January 2016. Data are due 1H 2019.
Emricasan
NASH fibrosis - ENCORE-NF trial
Phase 2 topline data released early January 2016
Emricasan
Liver Cirrhosis

Latest News

  1. Conatus Announces Completion of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
  2. Today's Research Reports on Stocks to Watch: Conatus Pharmaceuticals and Sangamo Therapeutics
  3. Conatus Announces Pricing of Public Offering of Common Stock
  4. Conatus Announces Proposed Public Offering of Common Stock
  5. Conatus (CNAT) Q1 Loss Narrows Y/Y, Revenues Beat Estimates
  6. Blog Coverage: Novartis Exercises Option for Global Development and Commercialization of Conatus Pharmaceuticals' Drug Emricasan
  7. Conatus reports 1Q loss
  8. Conatus Pharmaceuticals Reports First Quarter 2017 Financial Results and Program Updates
  9. Novartis exercises option with Conatus for NASH product
  10. Conatus Announces Exercise of License Option for Global Development and Commercialization of Emricasan Following Notice of Initiation of Phase 2b ENCORE-LF Clinical Trial in NASH Cirrhosis
  11. Can Conatus Pharma (CNAT) Deliver a Beat in Q1 Earnings?
  12. Conatus Pharmaceuticals to Report First Quarter 2017 Financial Results
  13. Conatus (CNAT) Catches Eye: Stock Moves Up 10% in Session
  14. Today's Research Reports on Stocks to Watch: Conatus Pharmaceuticals and Sonus Networks
  15. Conatus (CNAT) Up 57.7% Since Earnings Report: Can It Continue?
  16. Conatus Posters at EASL Meeting Address MELD Score Dynamics and Outcomes in Decompensated Liver Cirrhosis Patients, Including NASH Patients, Awaiting Liver Transplantation
  17. Are Options Traders Betting on a Big Move in Conatus Pharmaceuticals (CNAT) Stock?
  18. Conatus Pharmaceuticals and MannKind Look Forward to Promoting Their Brand
  19. Galectin Shares Upgraded To Buy; NASH-CX Results In December A 'Major Stock Catalyst'
  20. Conatus to Present at Upcoming Investor Conferences

SEC Filings

  1. 424B5 - Prospectus [Rule 424(b)(5)] 17835501
  2. 8-K - Current report 17835336
  3. 424B5 - Prospectus [Rule 424(b)(5)] 17831648
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 17815606
  5. 8-K - Current report 17813899
  6. 8-K - Current report 17811753
  7. DEF 14A - Other definitive proxy statements 17795727
  8. 8-K - Current report 17704265
  9. 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] 17694528
  10. 8-K - Current report 17691292